Alzheimer disease: From inherited to sporadic AD-crossing the biomarker bridge

Nature Reviews Neurology

Volumn 8, Issue 11, 2012, Pages 598-600

  Hampel, Harald ^a   Lista, Simone ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER; CRENEZUMAB; GLUCOSE; NEUROTRANSMITTER; PRESENILIN 1; PRESENILIN 2; TAU PROTEIN;

AAP GENE; ALZHEIMER DISEASE; APP GENE; AUTOSOMAL DOMINANT INHERITANCE; BLOOD ANALYSIS; BRAIN FUNCTION; BRAIN LEVEL; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ASSESSMENT; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEMENTIA; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE COURSE; DISEASE MODEL; DNA SEQUENCE; DOMINANT INHERITANCE; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; INHERITANCE; LIFESTYLE; MATHEMATICAL MODEL; MEMORY DISORDER; MOLECULAR DYNAMICS; MOLECULAR GENETICS; MOLECULAR MECHANICS; NERVE DEGENERATION; NEUROIMAGING; ONSET AGE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PSEN1 GENE; PSEN2 GENE; PSYCHOMETRY; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; SYMPTOMATOLOGY; SYSTEMS BIOLOGY;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; DISEASE PROGRESSION; GENETIC MARKERS; HUMANS;

EID: 84868582421     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2012.202     Document Type: Short Survey

References (10)

1. Tremlett, H. et al. Natural, innate improvements in multiple sclerosis disability. Mult. Scler. http://dx.doi.org/10.1177/1352458512439119.
2. [No authors listed] Double-masked trial of azathioprine in multiple sclerosis. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Lancet 2, 179-183 (1988).
3. Jacobs, L. D. et al. Intramuscular interferon beta-1a for disease progression in relapsingYremitting multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 39, 285-294 (1996).
4. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon beta 1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon beta 1a in secondary progressive MS. Clinical results. Neurology 56, 1496-1504 (2001).
5. Liu, C. & Blumhardt, L. D. Disability outcome measures in therapeutic trials of relapsingYremitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts. J. Neurol. Neurosurg. Psychiatry 68, 450-457 (2000).
6. Ebers, G. C., Heigenhauser, L., Saumer, M., Lederer, C. & Noseworthy, J. H. Disability as an outcome in MS clinical trials. Neurology 71, 624-631 (2008).
7. Coles, A. et al. Alemtuzumab versus interferon β-1a in early relapsingYremitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurology 10, 338-348 (2011).
8. Albrecht, H. Day to day variability of maximum walking distance in MS patients can mislead to relevant changes in the Expanded Disability Status Scale (EDSS): average walking speed is a more constant parameter. Mult. Scler. 7, 105-109 (2001).
9. de Weerd, A. W. Variability of central conduction in the course of multiple sclerosis. Clin. Neurol. Neurosurg. 89, 9-15 (1987).
10. Guthri, T. C. & Nelson, D. A. Influence of temperature changes on multiple sclerosis: critical review of mechanisms and research potential. J. Neurol. Sci. 129, 1-8 (1995).